About
Technology
Issues
FAQ
Links
Official Page
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.